Apoha

Name: Apoha
Brand: Apoha

AI Native

Pioneering the deployment of sensory intelligence with Liquid Brain®

Est 2021|Valuation $33.4M|2 Ref Customers

LinkedIn 4K|Website|FTEs 29|HQ London, United Kingdom

Published Oct 15, 2026

01Common complaints

If you require extensive independent validation and peer-reviewed evidence before using a metric for high-stakes go/no-go decisions
- Many vendor-published performance claims require independent verification. If your organization cannot perform internal benchmarking during evaluation, risk increases.
If you need a mature, full ELN/LIMS platform
- Apoha is not positioned as a replacement for ELN/LIMS products.
If you require publicly available enterprise security attestations
- No public SOC 2/ISO documentation was identified in accessible sources; organizations requiring such attestations up front may find this a procurement blocker.
If your workflow cannot accommodate sample shipment or external measurement
- Liquid Brain measurements appear to require sending material to the vendor for analysis, which may conflict with IP controls, biosafety constraints, or logistics timelines.
If you need predictable product behavior and durable storage during pilot
- The vendor’s beta usage policy explicitly warns that functionality may change and that data may be reset.
If budget constraints require published pricing and straightforward ROI modeling
- Liquid Brain and enterprise pricing are not publicly disclosed, increasing procurement friction.
Current limitations acknowledged by the vendor
- Beta status
  - The vendor’s usage policy states the platform is in beta, that feature availability and caps may change, and that the vendor may reset data during early access.
Roadmap / future features
- Not clearly published in the sources reviewed.
Scale limitations
- Vendor materials reference 96-well formats and per-sample run times, but throughput at scale (e.g., hundreds to thousands of molecules per week) is not independently validated in public sources.
Security/compliance gaps (public documentation gaps)
- No public SOC 2 or ISO 27001 attestations were identified.
- No public documentation for SSO/SAML, SCIM, audit logs, or data residency options was found.
API limitations
- The vendor states that data is accessible via an API, but API documentation was not found in the materials reviewed.

- If you require extensive independent validation and peer-reviewed evidence before using a metric for high-stakes go/no-go decisions - Many vendor-published performance claims require independent verification. If your organization cannot perform internal benchmarking during evaluation, risk increases. - If you need a mature, full ELN/LIMS platform - Apoha is not positioned as a replacement for ELN/LIMS products. - If you require publicly available enterprise security attestations - No public SOC 2/ISO documentation was identified in accessible sources; organizations requiring such attestations up front may find this a procurement blocker. - If your workflow cannot accommodate sample shipment or external measurement - Liquid Brain measurements appear to require sending material to the vendor for analysis, which may conflict with IP controls, biosafety constraints, or logistics timelines. - If you need predictable product behavior and durable storage during pilot - The vendor’s beta usage policy explicitly warns that functionality may change and that data may be reset. - If budget constraints require published pricing and straightforward ROI modeling - Liquid Brain and enterprise pricing are not publicly disclosed, increasing procurement friction. - Current limitations acknowledged by the vendor - Beta status - The vendor’s usage policy states the platform is in beta, that feature availability and caps may change, and that the vendor may reset data during early access. - Roadmap / future features - Not clearly published in the sources reviewed. - Scale limitations - Vendor materials reference 96-well formats and per-sample run times, but throughput at scale (e.g., hundreds to thousands of molecules per week) is not independently validated in public sources. - Security/compliance gaps (public documentation gaps) - No public SOC 2 or ISO 27001 attestations were identified. - No public documentation for SSO/SAML, SCIM, audit logs, or data residency options was found. - API limitations - The vendor states that data is accessible via an API, but API documentation was not found in the materials reviewed.

Deal disqualifiers: what makes a POOR fit

Organizations needing only an ELN/LIMS or sample tracking system.
Procurement processes that require public SOC 2/ISO documentation prior to any evaluation.
Organizations that cannot tolerate beta-product volatility or externalization of sensitive sequences.

02Why they buy

Value propositions supported by available evidence (mostly vendor-published)
- A time-series experimental measurement that produces thermodynamic/biophysical fingerprints under programmable stress conditions, which differs from static sequence/structure descriptors.
- Vendor-published claims of low sample input requirements (reported as 10 µg) and moderate per-sample run times.
- A unified workspace concept that integrates sequences, assay results, in-silico predictors, and Liquid Brain outputs for candidate triage.
- Public dataset hosting on a dataset platform, which provides some degree of transparency into vendor data and analyses.
Areas where competitors have established advantages
- Schrödinger: established computational biologics workflows and maturity in structure-based design.
- Benchling: broad adoption as an operational R&D platform and a system-of-record for lab workflows.
- Established assay vendors and internal pipelines: known reliability, familiar failure modes, and easier regulatory defensibility in some contexts.

- Value propositions supported by available evidence (mostly vendor-published) - A time-series experimental measurement that produces thermodynamic/biophysical fingerprints under programmable stress conditions, which differs from static sequence/structure descriptors. - Vendor-published claims of low sample input requirements (reported as 10 µg) and moderate per-sample run times. - A unified workspace concept that integrates sequences, assay results, in-silico predictors, and Liquid Brain outputs for candidate triage. - Public dataset hosting on a dataset platform, which provides some degree of transparency into vendor data and analyses. - Areas where competitors have established advantages - Schrödinger: established computational biologics workflows and maturity in structure-based design. - Benchling: broad adoption as an operational R&D platform and a system-of-record for lab workflows. - Established assay vendors and internal pipelines: known reliability, familiar failure modes, and easier regulatory defensibility in some contexts.

03Field reports

Important limitation (review availability)
- Apoha appears to be early-stage with limited presence on mainstream software review platforms under the exact product/company name.
- Attempts to find Apoha listings/reviews on Gartner Peer Insights, G2, TrustRadius, Capterra, and PeerSpot did not surface an accessible Apoha product listing with review content in the searches performed.
Vendor-published testimonials (summary)
- Company web materials include a testimonial from Dr. Nimish Gera (Scientific Co-Founder, VP) describing operational benefits such as analyzing larger assay volumes within an encrypted environment, reproducing results more quickly, accelerating go/no-go decisions, and adding Liquid Brain data to prioritize candidates.
- A testimonial attributed to Mythic Therapeutics describes that conventional assays provided limited dynamic range or resolution early in their workflow; it states that the Liquid Brain produced data from very small sample inputs, that the vendor ran multiple pilot programs including a multi-antibody case study, and that the system identified differences between antibodies with minimal sequence differences.
Community/social discussions (critical/neutral)
- Searches on Reddit and Hacker News primarily returned results about the philosophical term "apoha" rather than the company. No high-signal community threads about the company/product were found in accessible results during this research.
What customers appear to choose Apoha for (based on available evidence)
- Early-stage developability triage where sample amounts are limited.
- Capturing dynamic/time-series behavior under stress rather than single-point measurements.
- Combining experimental "state" data with existing assays and predictors inside a unified workspace.
Why customers might avoid / leave (inferred due to lack of public churn reviews)
- Because independent user reviews are not readily available, churn reasons cannot be validated from review platforms. Likely causes (hypothesis requiring customer validation) include:
  - Risk tolerance related to a novel measurement modality and proprietary scoring.
  - Integration friction with existing ELN/LIMS and data governance.
  - Budget constraints relative to established toolchains.
  - Reproducibility and validation requirements in regulated pipelines.

- Important limitation (review availability) - Apoha appears to be early-stage with limited presence on mainstream software review platforms under the exact product/company name. - Attempts to find Apoha listings/reviews on Gartner Peer Insights, G2, TrustRadius, Capterra, and PeerSpot did not surface an accessible Apoha product listing with review content in the searches performed. - Vendor-published testimonials (summary) - Company web materials include a testimonial from Dr. Nimish Gera (Scientific Co-Founder, VP) describing operational benefits such as analyzing larger assay volumes within an encrypted environment, reproducing results more quickly, accelerating go/no-go decisions, and adding Liquid Brain data to prioritize candidates. - A testimonial attributed to Mythic Therapeutics describes that conventional assays provided limited dynamic range or resolution early in their workflow; it states that the Liquid Brain produced data from very small sample inputs, that the vendor ran multiple pilot programs including a multi-antibody case study, and that the system identified differences between antibodies with minimal sequence differences. - Community/social discussions (critical/neutral) - Searches on Reddit and Hacker News primarily returned results about the philosophical term "apoha" rather than the company. No high-signal community threads about the company/product were found in accessible results during this research. - What customers appear to choose Apoha for (based on available evidence) - Early-stage developability triage where sample amounts are limited. - Capturing dynamic/time-series behavior under stress rather than single-point measurements. - Combining experimental "state" data with existing assays and predictors inside a unified workspace. - Why customers might avoid / leave (inferred due to lack of public churn reviews) - Because independent user reviews are not readily available, churn reasons cannot be validated from review platforms. Likely causes (hypothesis requiring customer validation) include: - Risk tolerance related to a novel measurement modality and proprietary scoring. - Integration friction with existing ELN/LIMS and data governance. - Budget constraints relative to established toolchains. - Reproducibility and validation requirements in regulated pipelines.

Vendor-published case study claims (antibody developability)

The vendor describes a VIBE (Variations in Interfacial Behavior and their Evolution) measurement that produces time-series data under stress and publishes aggregate summaries for a set of monoclonal antibodies. Claims include a published dataset on a public platform and asserted correlations between VIBE-derived scores and clinical-stage retention/progression outcomes. The vendor also reports small sample input amounts and short run-time estimates per sample, and provides comparisons to traditional assay panels.
Critical evaluation
- These are vendor-published claims; independent replication is not provided in publicly accessible sources. Claimed correlations between scores and clinical-stage outcomes may be affected by confounding factors (selection effects, survivorship bias, differences in modality or formulation). Buyers should request the full experimental protocol, raw data, and statistical analysis to assess validity and generalizability.

- The vendor describes a VIBE (Variations in Interfacial Behavior and their Evolution) measurement that produces time-series data under stress and publishes aggregate summaries for a set of monoclonal antibodies. Claims include a published dataset on a public platform and asserted correlations between VIBE-derived scores and clinical-stage retention/progression outcomes. The vendor also reports small sample input amounts and short run-time estimates per sample, and provides comparisons to traditional assay panels. - Critical evaluation - These are vendor-published claims; independent replication is not provided in publicly accessible sources. Claimed correlations between scores and clinical-stage outcomes may be affected by confounding factors (selection effects, survivorship bias, differences in modality or formulation). Buyers should request the full experimental protocol, raw data, and statistical analysis to assess validity and generalizability.

Customer pilot claims (Mythic Therapeutics summary)

Vendor materials describe a case study involving dozens of antibodies and claim detection of liabilities between closely related antibodies (small sequence differences).
Critical evaluation
- Testimonials and case study summaries are informative but anecdotal. Buyers should request ground-truth definitions (how liabilities are defined and confirmed), evidence of prospective prediction (rather than retrospective correlation), false positive/negative rates, and decision-impact analyses (how many candidates would have been incorrectly discarded or promoted).

- Vendor materials describe a case study involving dozens of antibodies and claim detection of liabilities between closely related antibodies (small sequence differences). - Critical evaluation - Testimonials and case study summaries are informative but anecdotal. Buyers should request ground-truth definitions (how liabilities are defined and confirmed), evidence of prospective prediction (rather than retrospective correlation), false positive/negative rates, and decision-impact analyses (how many candidates would have been incorrectly discarded or promoted).

Public dataset presence (dataset hosting)

The vendor hosts a dataset on a public dataset platform describing case studies, including statements about single-shot classification and comparative performance versus panels of biophysical assays.
Critical evaluation
- Public dataset hosting is a positive transparency signal, but dataset documentation and provenance should be independently reviewed. Buyers should inspect dataset fields, licensing, label provenance, and whether reported performance metrics use appropriate held-out test sets.

- The vendor hosts a dataset on a public dataset platform describing case studies, including statements about single-shot classification and comparative performance versus panels of biophysical assays. - Critical evaluation - Public dataset hosting is a positive transparency signal, but dataset documentation and provenance should be independently reviewed. Buyers should inspect dataset fields, licensing, label provenance, and whether reported performance metrics use appropriate held-out test sets.

04Best fit

Company sizes

Likely best fit:
- Biotech and biopharma R&D teams with active antibody discovery programs (from small/mid biotech to large pharma innovation groups).
- Teams with structured developability funnels that can incorporate additional experimental data.

Industries and verticals

Biopharma/biotech (therapeutic antibodies, fragments, bispecifics, ADCs, nanobodies).
Longer-term potential: materials science and industrial R&D (food, paints, other materials) per vendor messaging.

Roles and personas

Decision makers
- Heads of biologics discovery, protein engineering leads, CMC/developability leaders, translational research leadership, innovation/platform heads.
End users
- Bench scientists conducting candidate screening and stress studies.
- Computational scientists and data scientists integrating measurement outputs into models and pipelines.

Pain points and challenges the product addresses

Limited sample availability in early-stage screening.
Fragmented data across spreadsheets and tools; lack of consistent triage logic.
Late-stage developability failures that increase cost and timeline.

Qualification criteria: what makes a GOOD fit

Pipelines where earlier developability calls materially reduce downstream cost and time.
Willingness to pilot a novel measurement modality and perform rigorous internal validation.
Operational capacity to handle sample shipment/handling and to incorporate results into decision gates.

Real customer examples

Mythic Therapeutics is referenced on the vendor site as having run multiple pilot programs.

05The pitch

What the product does (core value proposition in objective terms)

Apoha describes a vendor-developed measurement and analytics approach called Liquid Brain that generates high-dimensional, time-series "state" (thermodynamic/biophysical) fingerprints of molecules/materials under programmable stress conditions. The company's current commercial focus is on antibody developability screening and triage.
Apoha provides a cloud software layer, the Apoha Insights Platform, which is presented as a workspace to consolidate sequence data, assay results, in-silico predictors (e.g., TAP/SAP-style metrics), and Liquid Brain readouts to support hit-to-lead decision processes.
Vendor materials position the platform as supporting earlier go/no-go decisions, reducing reliance on fragmented spreadsheets and tools, and making analytical outputs usable by bench scientists in addition to computational scientists.

- Apoha describes a vendor-developed measurement and analytics approach called Liquid Brain that generates high-dimensional, time-series "state" (thermodynamic/biophysical) fingerprints of molecules/materials under programmable stress conditions. The company's current commercial focus is on antibody developability screening and triage. - Apoha provides a cloud software layer, the Apoha Insights Platform, which is presented as a workspace to consolidate sequence data, assay results, in-silico predictors (e.g., TAP/SAP-style metrics), and Liquid Brain readouts to support hit-to-lead decision processes. - Vendor materials position the platform as supporting earlier go/no-go decisions, reducing reliance on fragmented spreadsheets and tools, and making analytical outputs usable by bench scientists in addition to computational scientists.

Target market and market positioning

Primary use case: biologics R&D teams conducting early antibody discovery, engineering, and developability risk screening (hit ID → lead triage).
Secondary/longer-term vision (based on press and website): applying Liquid Brain measurements to broader materials discovery (proteins, food products, paints/materials).
The offering is a hybrid of:
- An experimental measurement service/platform (Liquid Brain)
- A data and analytics software platform (Insights Platform)

- Primary use case: biologics R&D teams conducting early antibody discovery, engineering, and developability risk screening (hit ID → lead triage). - Secondary/longer-term vision (based on press and website): applying Liquid Brain measurements to broader materials discovery (proteins, food products, paints/materials). - The offering is a hybrid of: - An experimental measurement service/platform (Liquid Brain) - A data and analytics software platform (Insights Platform)

Get a comprehensive analysis of Apoha including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →